The Medical Letter on Drugs and Therapeutics
Delafloxacin (Baxdela) - A New Fluoroquinolone Antibiotic
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved delafloxacin (Baxdela – Melinta), an anionic fluoroquinolone antibiotic, for oral and parenteral treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is the first fluoroquinolone to be approved for treatment of MRSA.

ABSSSIs — The FDA's definition of an ABSSSI includes cellulitis/erysipelas, major cutaneous abscess, wound infection, or burn infection, with a minimum lesion size of 75 cm2 and symptoms of systemic infection. Patients with chronic infections such as diabetic foot and decubitus ulcer infections, human and animal bites, and necrotizing fasciitis are excluded from ABSSSI trials.1

STANDARD TREATMENT — In many parts of the US, purulent skin and soft-tissue infections are now ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Delafloxacin (Baxdela) - A New Fluoroquinolone Antibiotic
Article code: 1543a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian